

REGISTERED COMPANY NUMBER: 07955451 (England and Wales)
REGISTERED CHARITY NUMBER: 1147457

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2021
for
THE HPV AND ANAL CANCER FOUNDATION
LIMITED

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Contents of the Financial Statements
for the Year Ended 31 December 2021**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 14
Independent Examiner's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statements	18 to 26
Detailed Statement of Financial Activities	27 to 28

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Reference and Administrative Details
for the Year Ended 31 December 2021**

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St. John's Lane London EC1M 4BS
BANKERS	HSBC 455 Strand London WC2R 0RH

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2021 was £204,749 and expenditure was £255,874..

Reserves Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

Objectives and aims

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

KEY ACHIEVEMENTS IN 2021

NOMAN is an Island

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, 141 individuals - and their hundreds of supporters - have embraced the cause and our values. These NOMEN have raised awareness about HPV-cancers on a local, national, and international scale as well as funds to support our programmes.

The passion of our participants never ceases to amaze us, especially in the context of the COVID-19 pandemic. The NOMAN Campaign implemented the necessary parameters and covid regulations to enable our scheduled endurance and awareness events to take place.

2021 saw the return of the NOMAN is an Island: Race to End HPV campaign's flagship Barcelona - Ibiza ocean rowing events. NOMAN's ocean rowing race pits teams of amateur rowers against each other in a three-day sprint across the Mediterranean. Rowing across an ocean is like no other sport: it is as much about the crews' ability to cope mentally as it is about technique and physical strength. Such is the enthusiasm for the event, that in 2015 we introduced a return leg from Ibiza to Barcelona. The race has seen great interest amongst adventure seekers looking to benefit a cause. Rowers range from people with no prior experience to more seasoned rowers looking to attempt an ocean row before committing to a larger challenge such as the Pacific or Atlantic Oceans.

Undoubtedly the pandemic impacted sign ups for the 2021 edition. The uncertainty around travel restrictions lifted around 3 weeks before the races themselves, restricting the races to 2 crews for both legs of the race. Enquiries around participation for future editions remains aligned with pre pandemic numbers which indicates a return to pre pandemic levels of participation in 2023, for the 10th anniversary edition.

2021 also saw NOMAN riders take on Haute Route events at Crans-Montana and Ventoux. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provide unparalleled experiences with 3- or 7-day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, the Ventoux event saw a first with NOMAN lighting up the climbs in our ochre gold 'END HPV' socks. 300 attendees of the event wore the socks with pride and heard from NOMAN co-founder Tristan Almada on our mission to eliminate HPV cancers at the pre-stage briefing event.

Proving that lack of boats or bikes is no impediment to those passionate about ending cancer, our first cohort of runners took on the iconic London Marathon, racing the streets of the capital. We thank all our athletes for their sacrifice and energy as NOMEN.

We look forward to 2022 and building upon our Haute Route partnership and beginning to take the steps in preparation for the 10th anniversary Row to End HPV.

HPV ACTION EUROPE NETWORK

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

OBJECTIVES AND ACTIVITIES

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with the ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers.

The main achievements of the HPV Action Network in 2021 were as follows:

Securing commitment to eliminating HPV cancers in Europe's Beating Cancer Plan

Just 14 months after the establishment of the European HPV Action Network, we achieved a European Commission 'flagship' commitment to gender-neutral HPV vaccination. **As a result, for the first time, the EU will dedicate resources to eliminate all HPV-caused cancers.**

Europe's Beating Cancer Plan is the EU's roadmap to act against cancer, mobilising the collective power of EU members to deliver change to benefit its citizens. It entails four areas; prevention, early detection, diagnosis and treatment, and improving the quality of life of cancer patients and survivors. The section pertinent to our work is:

3.7 Saving Lives through Cancer Prevention: Preventing cancers caused by infections

"With dedicated funds under the EU4Health programme and other funding instruments, Europe's Beating Cancer Plan will support Member States' efforts to extend routine vaccination against human papillomaviruses of girls and boys - in order to eliminate cervical cancer and other cancers caused by human papillomaviruses. The objective is to vaccinate at least 90% of the EU target population of girls and to significantly increase the vaccination of boys by 2030".

The above is outlined as a 'flagship initiative on prevention'. Needless to say, this is a massive victory for our campaign and is indicative that our advocacy and case for action set out in 'Viral Protection: Achieving the Possible' has momentum.

You can read the full report [here](#).

Call for the establishment of an HPV Vaccine Tracker

In European Immunisation Week 2021 (26 April - 2 May), the European Cancer Organisation's HPV Action Network called for the establishment of an HPV Vaccine Tracker to be hosted by the European Centre for Disease Prevention and Control (ECDC). This monitoring system would provide invaluable information about EU Member States' progress towards meeting the Beating Cancer Plan's goal of eliminating the cancers caused by HPV.

10 out of 27 EU countries have gender-neutral national HPV vaccination programmes, and eight others have made a commitment to introduce HPV vaccination for boys. Uptake of the vaccine in many countries is well below 90% with second dose completion rates ranging from 14% in Luxembourg to 24% in France to 31% in Germany. No EU country has a vaccination rate of 90% or more for the second dose. In addition, uptake rates in boys by comparison to girls are also lower, in Italy the vaccination rate of boys is 40% of that of girls. It is clear however that the COVID19 pandemic has disrupted vaccination programmes and led to a significant fall in uptake rates.

OBJECTIVES AND ACTIVITIES

A HPV Vaccine Tracker would help monitor progress towards Europe's Beating Cancer Plan goals, indicate slow progress and countries where additional support may be required, in addition to helping encourage Member States to adopt best practice. It will be a key indicator to the world how the EU is contributing towards a global effort to eliminate HPV cancers. The optimal platform for the HPV Vaccine Tracker would be provided by the European Centre for Disease Prevention and Control (ECDC), an EU organisation that works to improve Europe's defences against infectious illnesses and has a strong track record of work on HPV-related issues. ECDC's COVID-19 vaccine tracker provides an ideal template for such a model.

Self-sampling and HPV screening in Europe

To eliminate cervical cancer, there must be a large rise in the use of HPV testing for cervical cancer screening.

Providing women and people with a cervix the chance to self-sample for HPV, often known as self-sampling is an important component of any national screening program. Self-sampling is especially useful for those who have trouble accessing normal screening facilities.

In a position paper published by the Network, the key points of recommendation were:

- Self-sampling should form a central component of national cervical cancer screening programmes.
- Self-sampling should be utilised to return screening rates to pre-pandemic levels.
- HPV self-sampling should be endorsed by the European Commission's guidelines on cervical cancer. There should also be guidance on effective delivery.
- Research should continue into the best methods of delivering effective self-sampling with high levels of uptake as part of cervical cancer screening programmes.

Numerous studies have shown that self-sampling may be as accurate as traditional testing and is well received by consumers. In one case study, it is being provided as an alternative to a clinician assessment in the Netherlands to positive response from participants.

The paper can be read in full [here](#).

HPV TESTIMONIES

The human papillomavirus (HPV) and the cancers it causes can devastate people's lives. We worked with survivors of HPV cancers to become advocates, empowered to tell their story. They explained how they were diagnosed with cancer and their emotions and experiences as they dealt with that, and then started treatment. They talk about the impact on their lives and on those around them, and whether they have been able to get back to a 'normal' life.

They also talk to us about their thoughts on HPV itself and the availability of vaccination, and whether they would like to see universal vaccination for men and women. Finally, they give us their message to patients and policymakers so that others can learn from their stories.

Future plans

The Network now has 47 members/stakeholders, shown [here](#):

<https://www.europeancancer.org/topic-networks/1:hpv-action.html>. In 2022 and beyond, the HPV Action Network will:

- Encourage and support the EC and EU Member States to implement Europe's Beating Cancer Plan.
- Make the case for action to address the impact of the pandemic on vaccination and screening programmes.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

- Identify countries in the region that are falling behind on vaccination and screening and encourage and support advocacy in countries where progress seems possible.
- Continue to develop HPV Testimonies.
- Build on the momentum created by the WHO's global strategy for cervical cancer elimination, Europe's Beating Cancer Plan, and recent research showing that vaccination can prevent up to 90% of cervical cancer cases.
- Publish research commissioned into an 'umbrella review of interventions used to improve HPV vaccine uptake in children, adolescents and young adults (to be completed Spring 2022)'
- Publish research commissioned into the current state of HPV vaccination and cervical cancer screening programmes across the European region

Getting stakeholders round the table

Director David Winterflood presented at several roundtables in 2021 on the opportunity provided by gender neutral vaccination programmes to end preventable cancer. In October, a study published in the Lancet reported that vaccinating girls against HPV in England had cut rates of cervical cancer by 87%. This is incredibly exciting news, and as the causal agent of 5% of all cancers, we can expect to see rates of all HPV cancers reduce significantly over the coming years with increased vaccination. To that effect, we renewed calls in the UK for a catch-up programme for boys who have missed out on this life-saving intervention following the expansion of the HPV vaccine programme in 2019.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 8,600 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer support program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2021, the HPVACF's Peer-to-Peer programme included 705 participants.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 4,600 people by the end of 2021. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 10,000 times by the end of the year.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

Anal Cancer Patient Conference

On September 25th, 2021, the Anal Cancer Foundation held the first virtual Anal Cancer Patient Conference.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and one-on-one which, for many people, was the first time they were meeting a fellow thriver.

We created this event as an opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

Over 440 people registered for the conference from 20 countries around the world. Feedback from participants included that, "this is, without doubt, one of the finest virtual conferences I've ever attended, personal and professional -- and I've attended a lot!," "thank you for this conference. It provided me with a lot of information and more confidence to share my own story and help others become more aware of this disease," and "superb conference - so informative and deeply touching! Really, thank you!"

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Drs. Joel Palefsky, Cathy Eng, Karyn Goodman, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and how to mitigate the various side effects of chemoradiation. Thrivers were given the opportunity to ask questions live, as well as to connect with one another. Anal Cancer Thriver and Activist Marcia Cross and Cervivor's Tamika Felder shared their own stories, guiding the audience in how to use their personal experiences to advance the fight against anal cancer.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube. We will hold another Anal Cancer Patient Summit in 2022.

NCCN treatment guidelines

In 2021, we were thrilled to partner with NCCN to create the first anal cancer treatment guide for patients, enabling patients and their caregivers to take charge of their own care and recovery!

The National Comprehensive Cancer Network is an alliance of 31 cancer centers in the USA, recognized for dealing with complex and/or rare cancers. NCCN Clinical Guidelines are the recognized standard for clinical direction and policy in cancer care and are among the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care-including physicians, nurses, pharmacists, payers, patients, and their families-with the ultimate goal of improving patient care and outcomes. The creation of a companion guide for patients is the next step forward in empowering patients with accessible information.

This new anal cancer treatment guide presents clinical information in an easy-to-read format for people with cancer and those who support them. The patient guideline is intended to:

- Equip patients and providers with the same information as that of their medical team
- Ensure that patients, no matter where they are treated, know what the experts agree upon as the standard of treatment and care
- Empower patients with knowledge about all of their treatment and care choices
- Allow patients to self-advocate for their own best care

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES ANCHOR Study

A ground-breaking randomised controlled national trial of 4,500+ people has shown that anal cancer can be prevented by routine screening and removal of precancerous cells. The ANCHOR Study hoped to improve patient outcomes for people with anal precancer and cancer by finding the best way to stop anal precancer from progressing to cancer. The Anal Cancer Foundation built and led the coalition of organizations that supported and pushed for the study.

ANCHOR stands for Anal Cancer HSIL Outcomes Research and the study investigated treating anal cancer precursor lesions to see if this reduced the cancer risk for people living with HIV. Conceived and led by Anal Cancer Foundation Scientific Advisory Board Member Dr. Joel Palefsky, ANCHOR aimed to recruit 5,000 people living with HIV and was randomized into two groups: treatment of anal precancer and a control group. The incidence of anal cancer is highest in people living with HIV.

What was ANCHOR researching?

Prevention and early detection are essential to ending anal cancer. Yet, despite its growing incidence and mortality, there are no national screening guidelines for anal cancer or precancer. The rates of cervical cancer reduced by 80% once doctors starting screening for and treating cervical precancer.

The hope was that the ANCHOR study would illustrate that treating anal precancer will reduce the risk of anal cancer. The Anchor study had two main objectives: to determine the effectiveness of screening for and treating anal precancer to reduce the incidence of anal cancer in HIV-positive men and women, and to create a bank of blood, anal swab, and tissue specimens to support critical scientific studies on how anal cancer progresses. There were two arms in the study: one arm that received treatment for anal precancer and a control arm that did not.

Ninety percent of anal cancer is caused by the human papillomavirus (HPV), which can cause changes to the skin around and inside the anus. These changes are called "high-grade squamous intraepithelial lesions" or HSIL. Not all anal HSIL will develop into cancer. Most HSIL will go away on their own, but some become cancer over time and can eventually spread to other parts of the body.

What were the outcomes?

For now, we know that NIH halted the study in fall 2021 due to the therapy's success in reducing the incidence of anal cancer. Researchers will compile the data and submit for publication after peer review. It is expected that the data will provide guidance on recommendations to make anal cancer prevention programs the standard of care for people at high risk of anal cancer.

What does this mean for the anal cancer community?

Anal cancer is currently rapidly increasing at 3% a year. More people are being diagnosed with late stage anal cancer than ever before.

We need standard methods to find it early. The study proved that treating anal precancer in people living with HIV, the group at most high-risk for developing anal cancer, reduces their cancer risk. The next step is ensuring this becomes the standard of care so that we can end anal cancer by finding it and treating it before it ever becomes cancer.

Taking Care of You: Tips and Exercises to Restore Your Pelvic Health After Anal Cancer Chemoradiation

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

On Anal Cancer Awareness Day, Sunday March 21st 2021, Anal Cancer Foundation co-founder Justine Almada and board-certified physical therapist Dr. Allison Romero, PT, DPT of Reclaim Pelvic Therapy hosted a webinar to discuss Taking Care of You: Tips and Exercises to Restore Your Pelvic Health after Anal Cancer Chemoradiation.

This hour-long webinar included an overview of the impacts of anal cancer treatment as well as a plan to care for the nerves, muscles, and fascia that are affected by chemoradiation. It ended with an audience-led Q & A.

The resources we discussed and the physical therapy exercises Dr. Romero demonstrated and recommended for daily practice can be accessed [here](#).

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

We look forward to being part of the next IANS conference which in 2022 will be held in New York City.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer support programme.

Our goal in 2021 continues to be ensuring more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

With the pandemic reducing the in-person resources available to the anal cancer community, the need for communication with our community was more important than ever. Our communications strategy focused on consistency and 'being useful', with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

- Returning users now make up 20.68% of visitors vs 16.14% in 2014
 - Peer to Peer support signups are up 28% on 2020 figures, and 241% vs 2014 figures
- Going forward, we aim to continue providing all the support the anal cancer community needs.

LOOKING AHEAD: 2022

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eradicate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV as pupils returned to schools in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13 year old boys is as high as possible. The interruption caused by the pandemic will undoubtedly affect vaccination rates in the UK and beyond. In the wake of a growing vaccine hesitancy sentiment, our work is more important than ever.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message. In 2022, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, furthering the reach of our message to prevent 5% of cancer, and providing the opportunity to reconnect with the cyclists within our community.

We will continue to provide anal cancer thrivers with information and support they need on their journey. In addition, our Peer to Peer support programme retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences. We are excited by the response to our "Ask the Expert" sessions and look forward to providing more touchpoints for our community with these and the patient conference in 2022.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

FINANCIAL REVIEW

Financial position

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2021 was £204,749 and expenditure was £255,874.

Reserves policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

Going concern

As stated in note 20, the Trustees have considered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document, structure and management

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on28.09.2022..... and signed on its behalf by:


.....
T Almada - Trustee

**Independent Examiner's Report to the Trustees of
The HPV and Anal Cancer Foundation
Limited**

Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
FCA
Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

Date:30/09/2022.....

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31 December 2021**

	Notes	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		2,083	-	2,083	17,061
Other trading activities	2	202,664	-	202,664	73,105
Investment income	3	2	-	2	20
Total		204,749	-	204,749	90,186
EXPENDITURE ON					
Raising funds	4	56,981	-	56,981	20,478
Charitable activities	5				
Care and Support		47,743	-	47,743	27,417
Awareness Raising		146,825	-	146,825	76,467
Research for a Cure		4,325	-	4,325	4,906
Total		255,874	-	255,874	129,268
NET INCOME/(EXPENDITURE)		(51,125)	-	(51,125)	(39,082)
RECONCILIATION OF FUNDS					
Total funds brought forward		114,089	13,100	127,189	166,271
TOTAL FUNDS CARRIED FORWARD		62,964	13,100	76,064	127,189

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet
31 December 2021**

	Notes	2021 £	2020 £
CURRENT ASSETS			
Debtors	14	327	218
Cash at bank		83,806	135,806
		84,133	136,024
CREDITORS			
Amounts falling due within one year	15	(8,069)	(8,835)
NET CURRENT ASSETS		76,064	127,189
TOTAL ASSETS LESS CURRENT LIABILITIES		76,064	127,189
NET ASSETS		76,064	127,189
FUNDS	17		
Unrestricted funds		62,964	114,089
Restricted funds		13,100	13,100
TOTAL FUNDS		76,064	127,189

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on28.09.2022..... and were signed on its behalf by:

.....
T Almada - Trustee

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial reporting standard 102 - reduced disclosure exemptions

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgments and key sources of estimation uncertainty

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

2. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Fundraising events	202,664	73,105

3. INVESTMENT INCOME

	2021	2020
	£	£
Deposit account interest	2	20

4. RAISING FUNDS

Raising donations and legacies

	2021	2020
	£	£
Staff costs	5,900	5,611
Development expenses	118	152
Donor software subscription	2,002	1,174
Event Expenses	46,842	4,226
Media	-	3,300
Support costs (Operating)	2,119	6,015
	56,981	20,478

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	34,986	-	12,757	47,743
Awareness Raising	113,037	17,365	16,423	146,825
Research for a Cure	2,808	-	1,517	4,325
	150,831	17,365	30,697	198,893

6. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2021 £	2020 £
Staff costs	33,429	15,713
Development Expenses	5,035	6,642
Marketing	43,064	12,939
Miscellaneous Expense	1,682	806
Event Expenses	46,843	4,226
Media	20,778	13,200
Internet and Website	-	6,545
	150,831	60,071

7. GRANTS PAYABLE

	2021 £	2020 £
Awareness Raising	17,365	13,235
The total grants paid to institutions during the year was as follows:		
	2021 £	2020 £
European Cancer Organisation	17,365	13,235

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

8. SUPPORT COSTS

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	41	1,602	476	2,119
Care and Support	71	11,859	827	12,757
Awareness Raising	143	14,626	1,654	16,423
Research for a Cure	19	1,275	223	1,517
	<u>274</u>	<u>29,362</u>	<u>3,180</u>	<u>32,816</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising £
Bank charges	41	71	143
Wages	-	-	-
Pensions	732	1,270	2,540
Rent and Rates	551	957	1,914
Insurance	71	125	250
Fees and subscriptions	-	357	357
Telephone, printing, postage and stationery	46	208	288
Sundries	77	135	270
Travel and Meetings	38	514	568
Staff Training	16	11	35
Consultancy fees	-	8,115	8,114
Conference expenses	71	167	290
Independent Examiner's fee	476	827	1,654
Accountancy and legal fees	-	-	-
	<u>2,119</u>	<u>12,757</u>	<u>16,423</u>
		2021	2020
	Research for a Cure £	Total activities £	Total activities £
Bank charges	19	274	177
Wages	-	-	16,082
Pensions	342	4,884	4,847
Rent and Rates	258	3,680	8,587
Insurance	34	480	244
Fees and subscriptions	-	714	413
Telephone, printing, postage and stationery	21	563	404
Sundries	37	519	831
Travel and Meetings	500	1,620	159
Carried forward	1,211	12,734	31,744

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

8. SUPPORT COSTS - continued

		2021	2020
	Research for a Cure £	Total activities £	Total activities £
Brought forward	1,211	12,734	31,744
Staff Training	5	67	-
Consultancy fees	-	16,229	5,439
Conference expenses	78	606	1,196
Independent Examiner's fee	223	3,180	2,640
Accountancy and legal fees	-	-	480
	1,517	32,816	41,499

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021	2020
	£	£
Independent Examiner's fee	3,180	3,000

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2021 nor for the year ended 31 December 2020.

11. STAFF COSTS

	2021	2020
	£	£
Wages and salaries	39,329	37,406
Other pension costs	4,884	4,847
	44,213	42,253

The average monthly number of employees during the year was as follows:

	2021	2020
	1	1

No employees received emoluments in excess of £60,000.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

11. STAFF COSTS - continued

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £39,329 (2020: £37,406).

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	17,061	-	17,061
Other trading activities	73,105	-	73,105
Investment income	20	-	20
Total	<u>90,186</u>	<u>-</u>	<u>90,186</u>
EXPENDITURE ON			
Raising funds	20,478	-	20,478
Charitable activities			
Care and Support	27,417	-	27,417
Awareness Raising	76,467	-	76,467
Research for a Cure	4,906	-	4,906
Total	<u>129,268</u>	<u>-</u>	<u>129,268</u>
NET INCOME/(EXPENDITURE)	(39,082)	-	(39,082)
RECONCILIATION OF FUNDS			
Total funds brought forward	153,171	13,100	166,271
TOTAL FUNDS CARRIED FORWARD	<u>114,089</u>	<u>13,100</u>	<u>127,189</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

13. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2021 and 31 December 2021	47,250
DEPRECIATION	
At 1 January 2021 and 31 December 2021	47,250
NET BOOK VALUE	
At 31 December 2021	-
At 31 December 2020	-

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Gift aid recoverable	327	-
Prepayments	-	218
	327	218

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Social security and other taxes	4,889	5,835
Accrued expenses	3,180	3,000
	8,069	8,835

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Current assets	71,033	13,100	84,133	136,024
Current liabilities	(8,069)	-	(8,069)	(8,835)
	62,964	13,100	76,064	127,189

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

17. MOVEMENT IN FUNDS

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	114,089	(51,125)	62,964
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	127,189	(51,125)	76,064

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	204,749	(255,874)	(51,125)
TOTAL FUNDS	204,749	(255,874)	(51,125)

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	153,171	(39,082)	114,089
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	166,271	(39,082)	127,189

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	90,186	(129,268)	(39,082)
TOTAL FUNDS	90,186	(129,268)	(39,082)

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

17. MOVEMENT IN FUNDS - continued

Capital fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2021.

19. GOING CONCERN

The Trustees have considered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charity's activities. While the outbreak is likely to cause some changes to the charity's business, the Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2021**

	2021 £	2020 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	2,083	17,061
Other trading activities		
Fundraising events	202,664	73,105
Investment income		
Deposit account interest	2	20
Total incoming resources	204,749	90,186
EXPENDITURE		
Raising donations and legacies		
Wages	5,900	5,611
Development expenses	118	152
Donor software subscription	2,002	1,174
Event Expenses	46,842	4,226
Media	-	3,300
	54,862	14,463
Charitable activities		
Wages	33,429	15,713
Development Expenses	5,035	6,642
Marketing	43,064	12,939
Miscellaneous Expense	1,682	806
Event Expenses	46,843	4,226
Media	20,778	13,200
Internet and Website	-	6,545
Grants to institutions	17,365	13,235
	168,196	73,306
Support costs (Operating)		
Finance		
Bank charges	274	177
Other		
Wages	-	16,082
Pensions	4,884	4,847
Rent and Rates	3,680	8,587
Carried forward	8,564	29,516

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2021**

	2021 £	2020 £
Other		
Brought forward	8,564	29,516
Insurance	480	244
Fees and subscriptions	714	413
Telephone, printing, postage and stationery	563	404
Sundries	519	831
Travel and Meetings	1,620	159
Staff Training	67	-
Consultancy fees	16,229	5,439
Conference expenses	606	1,196
	29,362	38,202
Governance costs		
Independent Examiner's fee	3,180	2,640
Accountancy and legal fees	-	480
	3,180	3,120
Total resources expended	255,874	129,268
Net expenditure	(51,125)	(39,082)

This page does not form part of the statutory financial statements